^
Association details:
| Biomarker: | ANGPT2-L |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma
Published date:
04/11/2020
Excerpt:
We identified patients with unresectable HCC who were treated with sorafenib or lenvatinib...All (9/9) patients with low baseline ANG2 and FGF19 levels who received lenvatinib achieved OR.
DOI:
10.1002/jgh3.12339
